Longitudinally extensive transverse myelitis is characteristic but not pathognomonic for neuromyelitis optica spectrum disorders (NMOSDs) and may mimic local tumors. In this retrospective study based on a cohort of 175 NMOSD patients we identified seven patients who initially presented with a longitudinally extensive spinal cord lesion and underwent spinal cord biopsy due to magnetic resonance imaging (MRI)-suspected malignancies. Remarkably, routine neuropathology was inconclusive and did not guide the diagnostic process to anti-aquaporin-4 (AQP4)-seropositive NMOSD. Serious postoperative complications occurred in 5/7 patients and persisted during follow-up in 2/7 patients (29%). Considering these sequelae, AQP4-antibody testing should be mandatory in patients with inconclusive longitudinally extensive spinal cord lesions prior to biopsy.
Introduction
Neuromyelitis optica (NMO) is an inflammatory demyelinating autoimmune disease with the key features of optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM), characterized by a spinal cord magnetic resonance imaging (MRI) lesion ≥3 vertebral segments. 1, 2 However, LETM is not pathognomonic for NMO spectrum disorders (NMOSDs), 1 as longitudinally extensive spinal cord lesions (LESCLs) can be observed with coexisting systemic autoimmune diseases, infections, vascular and metabolic disorders and following irradiation. [3] [4] [5] Moreover, intramedullary tumors or paraneoplastic myelopathies may present as LESCLs and thus mimic NMO-associated LETM. 3, 4 Usually, clinical history and presentation, neuroimaging findings as well as cerebrospinal fluid (CSF) and serological tests guide the diagnostic work-up of NMOSD, 6, 7 particularly after the recent discovery of highly specific anti-aquaporin-4 antibodies (AQP4-Abs). 8 However, in rare cases the identification of the underlying pathology is difficult, rendering spinal cord biopsy with potentially serious sequelae an ultimate means to rule out malignancies. Here, we retrospectively investigated the incidence and diagnostic value of spinal cord biopsy as well as the subsequent clinical outcome within a recently reported cohort of NMOSD patients. 7 
Methods
To identify NMOSD patients who underwent spinal cord biopsy we used the German Neuromyelitis Optica Study Group (NEMOS) as previously described (www.nemosnet.de). 9 At the time of analysis, 175 NMOSD cases as defined by Wingerchuk and colleagues in 2007 had been captured. 1, 7 Patients who underwent biopsy had been transferred for follow-up from neurosurgical and neurological hospitals to the Departments of Neurology in Düsseldorf or Berlin, Germany, and Hochegg, Austria. We were able to perform a neuropathological reevaluation in 4/7 cases, using the original biopsy specimens. The study was approved by the local ethics committees, and all patients gave written informed consent.
Results
We identified seven female NMOSD patients with a prior history of diagnostic spinal biopsy, six patients of Caucasian origin and one of Afro-American descent, while the other patients of our cohort did not undergo spinal biopsy. None of the patients had a prior brain biopsy. The median age was 40 years (range 24-52) at first clinical presentation and 43 years (range 29-57) at LETM/biopsy. LETM was the initial manifestation in four patients, three patients had experienced an inflammatory episode suggestive of NMOSD prior to biopsy (optic neuritis or rhombencephalitis; Table  1 ). Suspected diagnoses leading to biopsy 84 days after clinical onset (mean; range 8 days-10 months) included 'astrocytoma', 'atypical pen-like glioma', 'tumor of unknown etiology', 'spinal tumor' and 'intramedullary tumor'. Spinal MRI showed non-homogeneous gadolinium enhancement (in 6/7 patients) with pronounced myelon swelling between the medulla oblongata and Th9 (range), extending >6 segments (mean, range 4-15; Figure 1 ). Brain MRI prior to biopsy was normal in 4/7 patients or revealed unspecific white matter lesions in 3/7 cases. CSF analysis showed mild (5/7 patients) or moderate pleocytosis (2/7 patients) and isolated oligoclonal bands in one patient (Table 1) .
Remarkably, initial histopathological diagnoses did not suggest an NMO-related process but were reported as (a) 'inflammatory destructive lesion', (b) 'glial tumor with desmoplastic and angiogenic compound of low malignancy', (c) 'angiodysgenetic necrotizing myelopathy FoixAlajouanine', (d) 'subacute necrosis, no tumor', (e) 'tumorfree spinal cord', (f) 'central nervous system (CNS) tissue with severe reactive and resorptive changes, no neoplasia' and (g) 'reactive CNS tissue with inflammation and resorptive changes' ( Table 1) .
Reevaluation of four available biopsies was limited by the small sample size and numbers of sections. Demyelination was evident in all cases. Inflammation (CD3), extensive axonal damage (Bielschowsky silver impregnation) and hyalinized vessels were evident in 3/3 biopsies. Perivascular complement depositions were not found (0/3; C9neo) and complement within macrophages was evident in one case (1/3; C9neo). Only in one biopsy were eosinophilic granulocytes present. Both of the two cases in which Glial fibrillary acidic protein (GFAP) and AQP4 could be stained showed astrocytic dystrophy and loss as well as loss of AQP4. Oligodendrocytes (NOGO-A or CNPase staining) were depleted in 2/2 biopsies (see Supplementary Material).
All patients were AQP4-seropositive when tested after biopsy using cell-based assays. The final diagnoses were NMO (4/7) and NMO-related LETM (3/7) at an average of 68.4 months (range 0.5-160) after initial symptoms and 30.3 months (range 0.25-103.5) after biopsy (Table 1) . Notably, three patients were biopsied before AQP4-Ab testing was routinely available (one in 1995, two in 2002). 8 Testing was available but not performed before surgery in all other cases. Median Expanded Disability Status Scale (EDSS) prior to biopsy was 4.0 (range 2.5-8.0) and 8.0 (range 3.0-8.5) in the first few days thereafter, due to severe complications like CSF leakage, epidural hematoma (Figure 1 ), and postoperative spinal trauma in 5/7 patients. Biopsy-related deterioration persisted in 2/7 patients, with an elevated EDSS score of 7.5 (median; range 2.0-8.5) at last follow-up (mean 86.6 months after spinal biopsy; range 20-218).
Discussion
Undoubtedly, CNS biopsy represents the ultimate diagnostic step for evaluation of an unclear tissue alteration such as a longitudinally extensive spinal cord lesion. NMO histopathology in general is characterized by inflammatory, often destructive, demyelinating lesions with perivascular immunoglobulin G (IgG) and complement deposition, hyalinized vessels and eosinophilic granulocytes. An astrocytic pathology with AQP4 loss extending beyond the area of demyelination is typical and oligodendrocytes may be lost within lesions. 10, 11 However, invasive biopsy procedures may have adverse effects, particularly in the inflamed spinal cord. Moreover, in this case series, initial routine histopathology excluded tumors in 6/7 patients (Table 1) , but did not lead to the correct diagnosis. Five patients experienced transient postoperative complications shortly after biopsy, leading to persistent, severe paraparesis in one patient and permanent tetraparesis with wheelchair dependence in another. Obviously the proportion of severe post-operative complications was relatively high in our study, possibly due to the central localization of the spinal lesions as well as their inflammatory nature, leading to local hyperemia and thus an increased susceptibility to unintended bleeding events and edema. NMO-related LETM was only recognized after detection of NMO-IgG. Although histopathological reevaluation in four patients revealed some typical NMO features, a definite diagnosis was challenging despite familiarity with the AQP4 serosta- tus as certain neuropathological findings typical of NMOlike perivascular depositions of activated complement were not detectable. This observation is in line with previous reports suggesting heterogeneity of NMO lesions according to lesion stage, biopsy site and the paucity of typical spinal specimens. 10, 11 Our report confirms and extends a previous single case report 12 but has several limitations. The analysis is retrospective, and the patients were not recruited from a random population of patients with spinal lesions including confirmed cases of glioma but from a recently-described cohort of NMOSD patients. 7 Moreover, 3/7 patients were biopsied in 1995 and 2002 before the availability of NMO-IgG measuring. 8 However, our findings emphasize the importance of NMO-IgG testing for LETM. Considering the possible adverse effects of biopsy procedures, testing for NMO-IgG is justified in patients with unclear spinal cord tumors. In light of the heterogeneity of available assays and the low prevalence of NMOSD, a detection method with sufficient sensitivity and specificity should be used. 13 Biopsy of LESCLs should be limited to cases in which other tests only provide inconclusive diagnostic findings.
